Placebo matching with BMS-820836

DRUG2 trials

Sponsors

Bristol-Myers Squibb

Conditions

Depression

Phase 2

Efficacy and Safety of Flexibly Dosed BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression

CompletedNCT01309945

Bristol-Myers SquibbDepression

Start: 2011-04-30End: 2013-01-31Updated: 2015-10-12

Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression

TerminatedNCT01361555

Bristol-Myers SquibbDepression

Start: 2011-08-31End: 2013-10-31Updated: 2015-10-12